OBSERVATION {#h0.0}
===========

Gonorrhea remains a global health problem. The worldwide incidence of *Neisseria gonorrhoeae* infection equaled or surpassed that of *Chlamydia trachomatis* as the most common bacterial sexually transmitted infection for the first time in 2008 ([@B1]). Increasing bacterial resistance to antibiotics used to treat gonorrhea, coupled with a dearth of new antimicrobial therapies in development, raises the specter of incurable *N. gonorrhoeae* infections ([@B2]). The potential of adverse reproductive health consequences of untreatable gonococcal infections as well as increased HIV transmission in areas where both infections are prevalent is alarming ([@B3]). Identification of new therapeutic and vaccine targets for gonorrhea may be more important now than ever before.

The most abundant lipid constituent of the *N. gonorrhoeae* outer membrane is lipooligosaccharide (LOS), a glycolipid comprised of an antigenically variable oligosaccharide core ([@B4]) attached to lipid A, which is frequently decorated by phosphoethanolamine (PEA) at the 4′ position ([@B5], [@B6]). The presence or absence of PEA-decorated lipid A (PEA-lipid A) profoundly influences inflammatory signaling ([@B7], [@B8]) and bacterial susceptibility to innate host defenses, including the bactericidal activities of normal human serum, complement, and cationic antimicrobial peptides (CAMPs) ([@B5], [@B9]). To assess the importance of this structure during human infection, we constructed PEA transferase (*lptA*) deletion mutants of *N. gonorrhoeae* strain FA1090, which cannot add PEA to lipid A, and tested FA1090 Δ*lptA* in competitive infections with isogenic *lptA*^+^ gonococci in the female murine lower genital tract and the human male urethra.

Strains. {#h1}
--------

*N. gonorrhoeae* FA1090 is a porin serotype PIB-3, streptomycin (Sm)-resistant strain that has been used extensively in experimental human infection studies ([@B10]). Bacteria were cultured on gonococcal agar (GC agar) supplemented with Kellogg's supplement I and ferric nitrate or in GC broth as described previously ([@B11]) with or without antibiotics as appropriate. Cultures were incubated at 35 to 37°C with 5 to 7% CO~2~.

FA1090 Δ*lptA* was constructed without altering the antibiotic susceptibility of the wild-type strain, as previously described ([@B12]). Briefly, a two-gene cassette containing both a selectable marker (chloramphenicol \[Cm\] acetyltransferase \[CAT\] conferring Cm resistance) and a counterselectable marker (*rpsL*, conferring Sm sensitivity on the naturally resistant strain FA1090) was cloned into the *lptA* gene and used to replace the wild-type gene in the FA1090 chromosome by allelic exchange; transformants were selected on GC agar with 1 µg Cm/ml. The resulting intermediate strain was Cm resistant and Sm sensitive. A second transformation replaced the CAT *rpsL* cassette with an unmarked deletion encompassing approximately 80% of the *lptA* coding sequence; transformants were selected on GC agar with 100 µg Sm/ml. The resulting strain, FA1090 Δ*lptA*, was Cm sensitive and Sm resistant, as is wild-type strain FA1090. PCR amplification of the *lptA* locus and analysis of the FA1090 Δ*lptA* genome sequence confirmed deletion of the gene in the mutant. The wild-type *lptA* gene from strain FA19 (identical to that of FA1090) was introduced into the FA1090 deletion mutant using the pGCC4 *lptA*^+^ vector as previously described ([@B5]). The wild-type *lptA* gene is under the control of a *lac* promoter and is positioned between *lctP* and *aspC* in C′FA1090 Δ*lptA*.

Electrophoretic characterization of gonococcal LOS and lipid A biochemical analyses. {#h2}
------------------------------------------------------------------------------------

Whole-cell proteinase K-digested lysates of gonococci were resolved by Tricine-sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and LOS bands were identified by silver staining and Western blotting with monoclonal antibody 3F11 as previously described ([@B9]). Lipooligosaccharides were purified from *N. gonorrhoeae* strains grown in GC broth, and lipid A was isolated by mild acid hydrolysis as previously described ([@B9]). Lipid A was purified by extraction with chloroform and methanol; purified material was used for compositional analysis and determination of mass by matrix-assisted laser desorption ionization--time of flight mass spectrometry (MALDI-TOF MS) using a model 4700 proteomics analyzer instrument (Applied Biosystems). Oligosaccharides were purified by size exclusion column chromatography; linkage analysis was performed by gas chromatography-mass spectrometry (GC-MS) using an Alltech AT-1 fused-silica capillary column on a Hewlett-Packard HP5890 gas chromatograph equipped with mass selective detector 5970 MSD.

PMB MIC determination. {#h3}
----------------------

MICs of polymyxin B (PMB) were determined by spotting approximately 10^5^ CFU of *N. gonorrhoeae* suspensions onto GC agar containing 2-fold differences in PMB, from 0.19 to 200 µg PMB/ml; the MIC was defined as the highest concentration of PMB at which bacterial growth was observed after a 24-h incubation.

Experimental murine infection. {#h4}
------------------------------

All animal experiments were conducted at the Uniformed Services University of the Health Sciences according to the guidelines of the Association for the Assessment and Accreditation of Laboratory Animal Care under a protocol that was approved by the University's Institutional Animal Care and Use Committee. Female BALB/c mice (6 to 8 weeks old; National Cancer Institute) were treated with water-soluble 17β-estradiol and antibiotics to increase susceptibility to *N. gonorrhoeae* as described previously ([@B13]). Groups of mice were inoculated intravaginally with wild-type FA1090 combined with similar numbers of FA1090 Δ*lptA* or C′FA1090 Δ*lptA* CFU (total dose, 10^6^ CFU *N. gonorrhoeae*; 7 mice/group). Vaginal swabs were collected every other day for 6 days starting on day 2 postinoculation and suspended in 100 µl GC broth. Vaginal swab suspensions and inocula were cultured quantitatively on GC agar with 100 µg Sm/ml (total number of CFU) and GC agar with Sm plus 10 µg PMB/ml (FA1090 or C′FA1090 Δ*lptA* CFU).

Experimental human infection. {#h5}
-----------------------------

Procedures for participant recruitment, informed consent, intraurethral inoculation, and antibiotic treatment were as previously described ([@B11]). Experimental human infections were conducted in the Clinical and Translational Research Center of the North Carolina Translational and Clinical Sciences Institute at the University of North Carolina at Chapel Hill according to the guidelines of the U.S. Department of Health and Human Services and the University's Institutional Review Board under a protocol that was approved as a U.S. investigational new device (IND). All study participants provided written informed consent. In two separate trials, volunteers received approximately equal numbers of *N. gonorrhoeae* FA1090 and FA1090 Δ*lptA* CFU (total dose, 10^5^ to 10^6^ CFU *N. gonorrhoeae*; 3 men/trial). Gonococci in the inoculum suspensions were predominantly opacity-associated adhesin (Opa) negative and piliated and expressed the same PilE sequence as previously characterized FA1090 variants used in experimental human infection studies ([@B14]). First-void urine specimens were obtained daily after inoculation. Urine sediment was cultured quantitatively on GC agar with 3 µg vancomycin, 12.5 units nystatin, and 5 µg trimethoprim lactate/ml, which permits the growth of FA1090 and FA1090 Δ*lptA*. Up to 96 colonies per subject per culture were replica plated on GC agar with and without 7.5 µg colistin/ml to distinguish the 2 strains; only wild-type FA1090 grows in the presence of the polycationic antibiotic colistin.

Competitive index calculations and statistics. {#h6}
----------------------------------------------

For experimental murine and human infections, results were expressed as the competitive index (CI) for infected individuals using the equation CI = \[mutant CFU (output)/wild-type CFU (output)\]/\[mutant CFU (input)/wild-type CFU (input)\]. For murine infections, in which total CFU and wild-type CFU were enumerated directly from vaginal specimen cultures, the limit of detection of 1 CFU was assigned for a strain that was not recovered from an infected mouse. For human infections, in which total CFU were enumerated directly from urine sediment cultures and up to 96 CFU per specimen was subcultured to identify wild-type or mutant colonies, the limit of detection (1/96 CFU) was assigned for the output proportion of a strain that was not detected from an infected man. A CI of \<1 indicates that the mutant is less fit than the wild-type strain. For experimental human infections, we also compared the proportion of wild-type FA1090 among recovered *N. gonorrhoeae* isolates on the final day of participation for each infected subject to the proportion in the inoculum using a single-sample *t* test, with the proportion for the null hypothesis equal to 0.54 (the mean proportion of strain FA1090 in the inoculum). With a clearly directional hypothesis that the *lptA*^+^ strain would predominate, we used SigmaStat for Windows, v3.5 (Systat Software, Inc.), to calculate one-tailed statistics, with the type I error rate controlled at 0.05.

Lack of LptA-mediated PEA attachment to lipid A renders *N. gonorrhoeae* susceptible to a model CAMP *in vitro*. {#h7}
----------------------------------------------------------------------------------------------------------------

PEA addition at the 4′ position of FA1090 lipid A was abrogated in FA1090 Δ*lptA* and restored in the complemented strain C′FA1090 Δ*lptA* (see [Fig. S1A to D](#figS1){ref-type="supplementary-material"} in the supplemental material). All strains produced 4.2- and 4.5-kDa LOS species; the former reacted with monoclonal antibody 3F11 (data not shown), confirming the presence of the lacto-*N*-neotetraose epitope associated with naturally acquired gonococcal urethritis ([@B15]). As expected, deletion of *lptA* rendered FA1090 hypersusceptible to the model CAMP PMB (MICs, 100 µg PMB/ml for FA1090 versus 0.78 µg PMB/ml for FA1090 Δ*lptA*), which was reversed by 32-fold in the complemented strain (data not shown). Importantly, *in vitro* growth rates of FA1090 Δ*lptA* and wild-type FA1090 were indistinguishable (data not shown), and the Δ*lptA* mutant did not show a fitness difference from wild-type FA1090 when cocultured *in vitro* through stationary phase in the absence of selective pressure (data not shown). From mixtures containing similar numbers of Δ*lptA* mutant and wild-type FA1090 cells exposed to 5 µg PMB/ml for 45 min *in vitro*, only wild-type *N. gonorrhoeae* with PEA-lipid A survived (data not shown), confirming the importance of this structure in CAMP resistance.

LptA-mediated PEA attachment to lipid A confers a survival advantage to *N. gonorrhoeae* during competitive infection in mice. {#h8}
------------------------------------------------------------------------------------------------------------------------------

Experimental infection of female BALB/c mice has been used to study innate host defenses against *N. gonorrhoeae* and the mechanisms by which gonococci evade these defenses ([@B16]--[@B18]). Groups of female BALB/c mice were inoculated intravaginally with mixtures containing similar numbers of wild-type FA1090 and either FA1090 Δ*lptA* or C′FA1090 Δ*lptA* CFU (total dose, 5 × 10^6^ to 7 × 10^6^ CFU). The relative number of colonies of each strain recovered from vaginal swabs from infected mice was determined for up to 6 days after inoculation; output ratios of the two strains were normalized to the ratio of strains in the inoculum. We observed a 10- to 10,000-fold decrease in recovery of the *lptA* mutant relative to the wild-type parent strain FA1090 on days 2 to 6 of infection ([Fig. 1A](#fig1){ref-type="fig"}). No mutant bacteria were recovered from several mice on multiple days postinoculation, whereas wild-type gonococci were recovered from these mice at levels of \>10^3^ to \>10^6^ CFU/ml vaginal swab suspension ([Fig. 1A](#fig1){ref-type="fig"}, open circles). Complementation of *lptA* restored recovery of the mutant by day 6 postinoculation ([Fig. 1B](#fig1){ref-type="fig"}). Packiam et al. recently showed similar results with gonococcal strain FA19 during competitive infection in mice ([@B19]).

![PEA decoration of *N. gonorrhoeae* lipid A confers a competitive advantage during genital tract infection. The competitive index (CI) was equal to \[FA1090 Δ*lptA* or C′FA1090 Δ*lptA*/FA1090 (output)\]/\[FA1090 Δ*lptA* or C′FA1090 Δ*lptA*/FA1090 (input)\]. (A) Competitive infections in female BALB/c mice (*n* = 7) with FA1090 Δ*lptA* and FA1090; (B) female BALB/c mice (*n* = 7) with C′FA1090 Δ*lptA* and FA1090; (C) male volunteers (*n* = 6) with FA1090 Δ*lptA* and FA1090. Note the different *y* axis scale in panel C, imposed by the limit of detection of 100-fold-decreased fitness in experimental human infections. (A and C) A CI of \<1 indicates that the mutant is less fit than the wild type. Solid circles indicate mice from which both wild-type *N. gonorrhoeae* FA1090 and FA1090 Δ*lptA* were recovered (A) and both wild-type *N. gonorrhoeae* FA1090 and C′FA1090 Δ*lptA*/FA1090 were recovered (B). Open circles indicate infected mice or men from whom only wild-type *N. gonorrhoeae* FA1090 was recovered (A and C) or only C′FA1090 Δ*lptA* was recovered (B). Horizontal bars indicate geometric mean CIs.](mbo0061316760001){#fig1}

LptA-mediated PEA attachment to lipid A confers a survival advantage to *N. gonorrhoeae* in the male urethra. {#h9}
-------------------------------------------------------------------------------------------------------------

To determine potential influences of host restriction differences in mice and humans (as well as differences in female and male genital tracts) on the contribution of PEA-lipid A to *in vivo* gonococcal survival, we performed competitive infections with wild-type *N. gonorrhoeae* FA1090 and the *lptA* mutant in the human challenge model of gonococcal urethritis ([@B10]). Six subjects were inoculated intraurethrally with approximately equal mixtures of FA1090 and FA1090 Δ*lptA* (total dose, 10^5^ to 10^6^ CFU). Five subjects (83%) developed gonococcal urethritis 2 to 4 days after inoculation; one remained uninfected for 5 days after inoculation ([Table 1](#tab1){ref-type="table"}). The relative number of each strain recovered was determined by subculturing up to 96 colonies from each positive urine sediment culture on selective media; output ratios of the two strains were normalized to the ratio of strains in the inoculum. Among colonies tested, only wild-type FA1090 was recovered ([Table 1](#tab1){ref-type="table"}). We observed the maximum possible 100-fold decrease in the recovery of the *lptA* mutant relative to that of wild-type FA1090 on days 2 to 4 of infection ([Fig. 1C](#fig1){ref-type="fig"}).

###### 

Competitive infection of male volunteers with *N. gonorrhoeae* FA1090 and FA1090 Δ*lptA*^[*h*](#ngtab1.1)^

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial   Subject identifier   Inoculum\                Day of\                       Urethral swab\   Bacteriuria^[*c*](#ngtab1.4)^   Pyuria^[*d*](#ngtab1.5)^   Urethritis^[*e*](#ngtab1.6)^   \% wild-type gonococci         
                               size^[*a*](#ngtab1.2)^   treatment^[*b*](#ngtab1.3)^   culture                                                                                                                                   
  ------- -------------------- ------------------------ ----------------------------- ---------------- ------------------------------- -------------------------- ------------------------------ ------------------------ ----- ----------
  1       100                  5.8                      3                             \+               5.2                             6.9                        \+                             55                       ≥99   

  101     5.1                  4                        \+                            5.6              7.4                             \+                         55                             ≥99                            

  104     5.5                  5                        −                             ND               4.0                             −                          55                             ND                             

                                                                                                                                                                                                                                \<0.0001

  2       110                  5.7                      2                             \+               5.5                             6.8                        \+                             53                       ≥99   

  111     5.6                  3                        \+                            4.1              5.9                             \+                         53                             ≥99                            

  112     5.4                  4                        \+                            5.1              6.3                             \+                         53                             ≥99                            
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Log~10~ CFU *N. gonorrhoeae* inoculated intraurethrally.

Day postinoculation.

Log~10~ CFU *N. gonorrhoeae*/ml urine sediment on day of treatment.

Log~10~ white blood cells (WBC)/ml urine sediment on day of treatment.

Greater than 5.8 log~10~ WBC/ml urine sediment (equivalent to \>4 WBC/high-power field) on day of treatment.

The limit of detection for recovered FA1090 Δ*lptA* was 1/96 colonies characterized.

Single-sample *t* test for the percentage of wild-type FA1090 *lptA*^+^ recovered versus the mean percentage inoculated.

+, positive; −, negative; ND, none detected.

In our competitive infection studies, PEA-lipid A clearly provided a substantial fitness benefit to gonococci during infection, both in the human male urethra and in the murine female genital tract, compared to *N. gonorrhoeae* lacking PEA attached to lipid A. The mouse model likely underestimates the importance of PEA-lipid A during infection due to differences in human and murine complement-binding proteins. However, some factors are apparently not host restricted (e.g., CAMP-mediated killing of the *lptA* mutant), confirming that the murine model can provide important information regarding the pathogenesis of gonococcal infection that is translatable to humans. In the mouse model, reduced infectivity resulting from *lptA* deletion in *N. gonorrhoeae* strain FA19 occurs only during competitive infections; noncompetitive infections with wild-type FA19, the FA19 *ΔlptA* mutant, or the complemented FA19 *lptA* mutant produce similar kinetics of vaginal colonization and bacterial recovery ([@B19]). However, only wild-type *N. gonorrhoeae* FA19 and the complemented FA19 *lptA* mutant induce proinflammatory host responses to gonococcal infection in female mice. John and colleagues previously demonstrated reduced inflammatory stimulation of human THP-1 cells by an *lptA* null mutant of the related pathogen *N. meningitidis* and by commensal *Neisseria* species that lack *lptA* ([@B20]). Thus, PEA decoration of gonococcal lipid A not only increases inflammatory responses *in vitro* and during murine infection but also protects *N. gonorrhoeae* from the consequences of inflammation, including increased CAMP production. Experimental human infection studies with inocula containing only *N. gonorrhoeae* FA1090 or FA1090 Δ*lptA* are needed to confirm whether PEA-decorated lipid A plays dual immunostimulatory and protective roles during male urethral infection. The demonstrated impaired fitness of *N. gonorrhoeae* mutants lacking PEA in men and female mice validates gonococcal LptA as an important target for development of novel immunoprophylactic strategies or antimicrobial treatments for gonorrhea in males and females in the face of diminishing treatment options.

SUPPLEMENTAL MATERIAL {#h1.1}
=====================

###### 

*N. gonorrhoeae* FA1090 lipid A structures. Negative-ion MALDI-TOF mass spectra (showing \[M-H\]^−^ monoisotopic ions) of lipid A from wild-type FA1090 (A), FA1090 Δ*lptA* (B), and C′FA1090 Δ*lptA* (C). (D) Putative structures, with their calculated monoisotopic masses (M~mi~), for lipid A species 1 to 4 identified in the spectra. Species 3 and 4 with PEA residues at the 4′ position (circled) are absent in FA1090 Δ*lptA*. Ions due to the loss of water (−18 Da), a change in fatty acid length (e.g., C~14~ to C~12~, resulting in −28 Da), and sodiated species (+22 Da) were also observed. Ion 1860.60 was present in both wild-type FA1090 and C′FA1090 Δ*lptA* lipid A; its structure remains to be identified. Download

###### 

Figure S1, TIF file, 0.1 MB
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